GREENVILLE, SC, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Zylö Therapeutics, a nanotechnology-based biopharmaceutical company dedicated to bringing innovative technologies to multiple facets of medicine, announced that preclinical data, utilizing Zylö’s patented hydrogel-derived Nanopods™ to deliver endocannabinoids for the treatment of cutaneous lupus in an established animal model, will be presented for the first time.

Dr. Adam Friedman, Associate Professor of Dermatology at the George Washington School of Medicine and Health Sciences and co-inventor of the Nanopods™, will be directing session F003 ‘Treating Tumors and Inflammatory Skin Diseases with Immunomodulators and Biologics’ on Friday, February 16, 2018  9-11AM. During the session, he will present the entitled lecture “The Potential of Cannabinoids for the Treatment of Inflammatory and Neoplastic Diseases of the Skin.”

Dr. Friedman commented: “I will review the biology of the endocannabinoid system as it relates to the skin, present the available preclinical and clinical data on applications of cannabinoids for the treatment of inflammatory and neoplastic skin diseases, and present new data showing improved cutaneous delivery of cannabinoids through the skin utilizing nanotechnology and the robust impact on cutaneous lupus in a well-established animal model.”

Added Scott Pancoast, CEO of Zylö, “We are proud of the work of our scientists and their collaborators as they continue to demonstrate the therapeutic power of our Nanopod™ platform, and we look forward to Dr. Friedman’s presentation at the American Academy of Dermatology.”

About Zylö: Zylö is a preclinical biotechnology company that has an innovative sustained-release drug-delivery system that was developed at the Albert Einstein College of Medicine.  The delivery system uses patented hydrogel-derived nanoparticles, called Nanopods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents primarily through the skin. Notably, the Nanopod™ delivery system has successfully harnessed the therapeutic potential of Nitric Oxide (NO), one of the most powerful biomolecules produced by practically every cell in our bodies, but is notoriously short-lived and unstable. The topically applied Nanopod™ delivery system also addresses many limitations of other established and emerging therapeutic ingredients, such as curcumin, siRNA, and cannabinoids.

Zylö Therapeutics
Scott R. Pancoast
Chief Executive Officer
(858) 775-6710